Chemotherapy of respiratory viruses: Prospects and challenges

Drug Resistance Updates

Volumn 2, Issue 4, 1999, Pages 244-258

  Wyde, Philip R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PALIVIZUMAB; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR;

ADENOVIRUS; DRUG EFFICACY; HIGH RISK POPULATION; INFLUENZA VIRUS; MEASLES VIRUS; PARAINFLUENZA VIRUS; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; RHINOVIRUS; VACCINATION; VIRUS INFECTION;

EID: 0033177891     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0091     Document Type: Article

References (274)

1. Dasaraju P. V., Liu C. Infections of the Respiratory System. Baron S., Medical Microbiology. 1996;1103-1115 The University of Texas at Galveston, Galveston.
2. Couch R. B., Englund J. A., Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 102:1997;2-9.
3. Lui K. J., Kendal A. P. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health. 77:1999;712-716.
4. Claas E. C., Osterhaus A. D., van Beek R. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 351:1998;472-477.
5. L'vov D. K., Slepushkin A. N., Iamnikova S. S., Burtseva E. I. Influenza remains an unpredictable infection. Vopr Virusol. 43:1998;141-144.
6. La Via W. V., Marks M. I., Stutman H. R. Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment and prevention. J Pediatr. 121:1992;503-510.
7. Whimbey E., Couch R. B., Englund J. A. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis. 21:1995;376-379.
8. Whimbey E., Englund J. A., Couch R. B. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med. 102:1997;10-18.
9. Agius G., Dindinaud G., Biggar R. J. An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J Med Virol. 30:1990;117-127.
10. Falsey A. R., Cunningham C. K., Barker W. H. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis. 172:1995;389-394.
11. Fleming D. M., Cross K. W. Respiratory syncytial virus or influenza. Lancet. 342:1993;1507-1510.
12. Reed G., Jewett P. H., Thompson J., Tollefson S., Wright P. F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis. 175:1997;807-813.
13. Englund J. A., Piedra P. A., Whimbey E. Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am J Med. 102:1997;61-70.
14. ASM News. 56:1990;358-359.
15. Couch R. B. Rhinoviruses. Fields B. N., Knipe D. M., Howley P. M., Virology. 1996;713-734 Lippincott-Raven, Philadelphia.
16. Falsey A. R., McCann R. M., Hall W. J. The "common cold" in frail older persons: impact of rhinovirus and coronavirus in a senior center. J Am Geriatr Soc. 45:1997;707-711.
17. Busse W. W. The role of the common cold in asthma. J Clin Pharmacol. 39:1999;241-245.
18. Halperin S. A., Eggleston P. A., Beasley P. Exacerbations of asthma in adults during experimental rhinovirus infection. Am Rev Respir Dis. 132:1985;975-980.
19. Rakes C. P., Arruda E., Ingram J. M. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care - IgE and eosinophil analyses. Amer J Respir Crit Care Med. 159:1999;785-790.
20. Mallet R., Riberre M., Bonnenfant F., Labrune B., Reyrole L. Les pneumonpathies graves adenovirus. Arch Fr Pediatr. 23:1966;1057-1073.
21. Kasel J. A. Adenoviruses. Lennette E., Schmidt N. J., Diagnostic procedures for viral rickettsial and chlamydial infections. 1979;229-255 American Public Health Association, New York.
22. Heubner R. J., Rowe W. P., Chanock R. M. New recognized respiratory tract viruses. Annu Rev Microbiol. 12:1964;49-76.
23. Miller L. F., Rytel M., Pierce W. E., Rosenbaum M. J. Epidemiology of non-bacterial pneumonia among naval recruits. J Am Med Assoc. 185:1963;92-99.
24. Mogabgab W. J. Mycoplasma pneumonia and adenovirus respiratory illnesses in military and university personnel. Am Rev Respir Dis. 97:1968;345-358.
25. Siegel F. P., Dikman S. H., Arayata R. B., Bottone E. J. Fatal disseminated adenovirus 11 pneumonia in an agammaglobulinemic patient. Am J Med. 71:1981;1062-1067.
26. Zahradnik J. M., Spencer M. J., Parker D. D. Adenovirus infection in the immunocompromised patient. Am J Med. 68:1980;725-732.
27. McIntosh K. Coronaviruses. Fields B. N., Knipe D. M., Howley D. M., Virology. 1996;1095-1104 Lippincott-Raven, Philadelphia.
28. Smith F. I., Palese P. Variation in influenza virus genes - Epidemiological, pathogenic, and evolutionary consequences. Krug R. M., The influenza viruses. 1989;319-359 Plenum Press, New York.
29. Mossad S. B. Underused options for preventing and treating influenza. Cleve Clin J Med. 66:1999;19-23.
30. Belshe R. B., Mendelman P. M., Treanor J. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 338:1998;1405-1412.
31. Clements M. L., Makhene M. K., Karron R. A. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. J Infect Dis. 173:1996;44-51.
32. Jackson L. A., Holmes S. J., Mendelman P. M., Huggins L., Cho I., Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist (TM), administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine. 17:1999;1905-1909.
33. Tomoda T., Morita H., Kurashige T., Maassab H. F. Prevention of influenza by the intranasal adminstration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine. 13:1996;185-190.
34. Couch R. B. Advances in influenza virus vaccine research. Ann NY Acad Sci. 685:1993;803-812.
35. Clover R. D., Crawford S. A., Abell T. D., Ramsey C. N. Jr, Glezen W. P., Couch R. B. Effectiveness of rimantadine prophylaxis of children with families. Am J Dis Child. 140:1986;706-709.
36. Dolin R., Reichman R. C., Madore H. P., Maynard R., Linton P. N., Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 307:1982;580-584.
37. Hayden G. G., Monto A. S. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother. 29:1986;339-341.
38. Tominack R. L., Hayden F. G. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clinics North America. 1:1987;459-478.
39. Wingfield W. L., Pollack D., Grunert R. R. Therapeutic efficacy of amantadine HCI and rimantadine HCI in naturally occurring influenza A2 respiratory illness in man. N Engl J Med. 281:1969;579-584.
40. Bean B. Antiviral therapy: Current concepts and practices. Clin Microbiol. 5:1992;146-182.
41. Bukrinskaya A. G., Vorkunova N. K. Rimantadine hydrochloride blocks the second step of influenza virus uncoating. Arch Virol. 66:1980;275-282.
42. Richman D. D., Hostetler K. Y., Yazaki P. J., Clark S. Fate of influenza A virion proteins after entry into subcellular fractions of LLC cells and the effect of amantadine. Virology. 151:1986;200-210.
43. Sugrue R. J., Bahadur G., Zambon M. C., Hall-Smith M., Douglas A. R., Hay A. J. Specific structural alteration of the influenza hemagglutinin by amantadine. EMBO J. 9:1990;3469-3476.
44. Hay A. J., Wolstenholme A. J., Skehel J. J., Smith M. H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 4:1985;3021-3024.
45. Hay A. J. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol. 3:1992;21-30.
46. Shimbo K., Brassard D. L., Lamb R. A., Pinto L. H. Ion selectivity and activation of the M2 ion channel of influenza virus. Biophys J. 70:1996;1335-1346.
47. Hay A. J., Zambon M. C., Wolstenholme A. J., Skehel J. J., Smith M. H. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother. 18(suppl B):1986;19-29.
48. Douglas R. G. Jr. Prophylaxis and treatment of influenza. N Engl J Med. 322:1980;443-450.
49. Belshe R. B., Burk B., Newman F., Cerruti R. I., Sim I. S. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveilance. J Infect Dis. 159:1989;430-435.
50. Englund J. A., Champlin R. E., Wyde P. R. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis. 26:1998;1418-1424.
51. Wainright P. O., perdue M. L., Brugh M., Beard C. W. Amantadine resistance among hemagglutinin subtype 5 strains of avain influenza virus. Avian Dis. 35:1991;31-39.
52. Bernstein D. I., Reuman P. D., Sherwood J. R., Young E. C., Schiff G. M. Ribavirin small-particle-aerosol treatment of influenza B virus infection. Antimicrob Agents Chemother. 31:1988;761-764.
53. Gilbert B. E., Wilson S. Z., Knight V. Ribavirin small particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 27:1985;309-313.
54. Liss H. P., Bernstein J. M. Ribavirin aerosol in the elderly. Chest. 93:1988;1239-1241.
55. McClung H. W., Knight V., Gilbert B. E., Wilson S. Z., Quarles J. M., Divine G. W. Ribavirin aerosol treatment of influenza B virus infection. J Am Med Assoc. 249:1983;2671-2674.
56. Stein D. S., Creticos C. M., Jackson G. G. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother. 31:1987;1285-1287.
57. Wilson S. Z., Gilbert B. E., Quarles J. M. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother. 26:1984;200-203.
58. Rodriguez W. J., Hall C. B., Welliver R. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr. 125:1994;129-135.
59. Shigeta S., Mori S., Watanabe J. In vitro antimyxovirus and anti-human immunodeficiency virus activities of polyoxometalates. Antivir Chem Chemother. 6:1995;114-122.
60. Barnard D. L., Hill C. L., Gage T. Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes. Antiviral Res. 34:1997;27-37.
61. Lin Y. M., Flavin M. T., Schure R. Antiviral activities of biflavonoids. Planta Med. 65:1999;120-125.
62. Sudo K., Watanabe W., Konno K. Efficacy of RD3-0028 aerosol treatment gainst respiratory syncytial virus infection in immunosuppressed mice. Antimicrob Agents Chemother. 43:1999;752-757.
63. Judd A. K., Sanchez A., Bucher D. J., Huffman J. H., Bailey K., Sidwell R. W. In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob Agents Chemother. 41:1997;687-692.
64. Hastings J. C., Selnick H., Wolanski B., Tomassini J. E. Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother. 40:1996;1304-1307.
65. Tomassini J. E., Davies M. E., Hastings J. C. A novel antiviral agent which inhibits the endonuclease of influenza viruses. Antimicrob Agents Chemother. 40:1996;1189-1193.
66. D'Agostini C., Palamara A. T., Favalli C. Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. Int J Immunopharmacol. 18:1996;95-102.
67. Wong J. P., Saravolac E. G., Sabuda D., Levy H. B., Kende M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infections in mice. Antimicrob Agents Chemother. 39:1995;2574-2579.
68. Nagibina M. V., Neifakh E. A., Krylov V. F., Braginskii D. M., Kulagina M. G. The treatment of pneumonias in influenza using antioxidants. Ter Arkh. 68:1996;33-35.
69. Sidwell R. W., Huffman J. H., Bailey K. W., Wong M. H., Nimrod A., Panet A. Inhibitory effects of recombinant manganese superoxide dismutase on influenza virus infections in mice. Antimicrob Agents Chemother. 40:1996;2626-2631.
70. Kolocouris N., Foscolos G. B., Kolocouris A. Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J Med Chem. 37:1994;2896-2902.
71. Lee M. G., Kim K. H., Park K. Y., Kim J. S. Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses. Arch Virol. 141:1996;1979-1989.
72. Ball M. A., Utsunomiya T., Ikemoto K., Kobayashi M., Pollard R. B., Suzuki F. The antiviral effect of keishi-ni-eppi-ichi-to, a traditional Chinese herbal medicine on influenza A2 (H2N2) virus infection in mice. Experientia. 15:1994;774-779.
73. Nagai N. T., Urata M., Yamada H. In vivo anti-influenza virus activcity of Kampo (Japanese herbal) medicine 'Sho-seiryu-to' - effects on aged mice, against subtypes of A Viruses and B virus, and therapeutic effect. Immunopharmacol Immunotoxicol. 18:1996;193-208.
74. Nagai T., Moriguchi R., Suzuki Y., Tomimori T., Yamada H. Mode of action of the anti-influenza virus activity of plant flavonoid, 5,74′-trihydroxy-8-methoxyflavone, from the roots of Scutellaria baicalensis. Antiviral Res. 26:1995;11-25.
75. Utsunomiya T., Kobayashi M., Pollard R. B., Suzuki F. Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob Agents Chemother. 41:1999;551-556.
76. Zakay-Rones Z., Varsano N., Zlotnik M. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elderberry extract (Sambucus nigra L.) during an outbreak of influenza B Panama. J Altern Complement Med. 1:1995;361-369.
77. Hisaki M., Imabori H., Azuma M. Synthesis and anti-influenza virus activity of novel pyrimidine derivatives. Antiviral Res. 42:1999;121-137.
78. Liu C., Eichelberger M. C., Compans R. W., Air G. M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol. 69:1995;1099-1106.
79. Palese P., Compans R. W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol. 33:1976;159-163.
80. Burnett F. M. Mucins and mucoids in relation to influenza virus action. Aust J Exp Biol Med Sci. 26:1948;381-387.
81. Colman P. M., Hoyne P. A., Lawrence M. C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol. 67:1993;2972-2980.
82. von Itzstein M., Wu W-Y., Kok G. B. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
83. Palese P., Schulman J. L. Oxford J. S., Chemoprophylaxis and virus infections of the upper respiratory tract. 1977;189-205 CRC Press, Cleveland.
84. Burmeister W. P., Ruigrok R. W., Cusack S. A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11:1992;49-56.
85. Colman P. M., Varghese J. N., Laver W. G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature. 303:1983;41-44.
86. Varghese J. N., Laver W. G., Colman P. M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature. 303:1983;35-40.
87. Hayden F. G., Rollins B. S., Madren L. K. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res. 25:1994;123-131.
88. Thomas G. P., Forsyth M., Penn C. R., McCauley J. W. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res. 24:1994;351-356.
89. Woods J. M., Bethell R. C., Coates J. A. V. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 37:1993;1473-1479.
90. Ryan D. M., Ticehurst J., Dempsey M. H., Penn C. R. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antivir Chem Chemother. 38:1994;2270-2275.
91. Ryan D. M., Ticehurst J., Dempsey M. H. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother. 39:1995;2583-2584.
92. Calfee D. P., Peng A. W., Cass L. M., Lobo M., Hayden F. G. Safety and efficacy of I intraveneous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agent Chemother. 43:1999;1616-1620.
93. Hayden F. G., Osterhaus A. D. M. E., Treanor J. J. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med. 337:1997;874-880.
94. Hayden F. G., Treanor J. J., Betts A. F. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J Am Med Assoc. 275:1997;295-299.
95. Li W., Escarpe P. A., Eisenburg E. J. Identification of GS 4104 as an orally bioavailable prodrug of the influenza neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother. 42:1998;647-653.
96. Lancet. 352:1998;1877-1881.
97. Monto A. S., Fleming D. M., Henry D. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis. 180:1999;254-261.
98. Monto A. S., Robinson D. P., Herlocher M. L., Hinson J. M. Jr, Elliott M. J., Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. J Am Med Assoc. 282:1999;31-35.
99. Schilling M., Povinelli L., Krause P. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine. 16:1998;1771-1774.
100. Kollmayer, B. Glaxo gets FDA approval for flu drug. CBS Market Watch. http://www.CBS.marketwatch.com. [accessed 7/27/99], 1, 2.
101. Gubareva L. V., Bethell R., Hart G. J. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol. 70:1996;1818-1827.
102. McKimm-Breschkin J. L., Blick T. J. S. A., Tiong T. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother. 40:1996;40-46.
103. Tai C. Y., Escarpe P. A., Sidwell R. W. Characterization of human influenza virus variants selected in vitro in the presence of neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother. 42:1998;3234-3241.
104. Sidwell R. W., Huffman J. H., Barnard D. L. Inhibition of influenza A virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res. 37:1998;107-120.
105. Gubareva L. V., Matrosovich M. N., Brenner M. K., Bethell R. C., Webster R. G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 178:1998;1257-1262.
106. Penn C. R., Barrett J. M., Bethell R. C. Selection of influenza virus with reduced sensitivity in vitro to the neuraminidase inhibitor compensate for loss of neuraminidase activity. Brown L. E., Hampson A. W., Webster R. G., Options for the control of influenza III. 1996;735-740 Elsevier, Amsterdam.
107. Blick T. J., Sahasrabudhe A., McDonald M., Morley P. J., Fenton R. J., McKimm-Breschkin J. L. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology. 246:1998;95-103.
108. Murphy B. R., Hall S. L., Kulkarni A. B. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (piv3) vaccines. Virus Res. 32:1994;13-36.
109. Crowe J. E. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV)-a meeting report of the WHO programme for vaccine development. Vaccine. 13:1995;415-421.
110. Groothuis J. R. The role of RSV neutralizing antibodies in the treatment and prevention of respiratory syncytial virus infection in high-risk children. Antiviral Res. 23:1994;1-10.
111. Ottolini M. G., Hemming V. G. Prevention and treatment recommendations for respiratory syncytial virus infection - Background and clinical experience 40 years after discovery. Drugs. 54:1997;867-884.
112. Pediatrics. 99:1997;645.
113. Weltzin R., Hsu S. A., Mittler E. S., Georgakopoulos K., Monath T. P. Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother. 38:1994;2785-2791.
114. Weltzin R., Traina-Dorge V., Soike K., Zhang J. Y., Mack P., Soman G. T., Dragik G., Monath T. P. Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 174:1996;256-261.
115. Wyde P. R., Moore D. K., Hepburn T., Silverman C. L., Porter T. G., Gross M., Taylor G., Demuth S. G., Dillon S. B. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats. Pediatr Res. 38:1995;543-550.
116. Johnson S., Oliver C., Prince G. A. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 176:1997;1215-1224.
117. Null D., Bimle C., Weisman L. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 102:1998;531-537.
118. Pediatrics. 92:1993;501-504.
119. Rodriguez W. J., Kim H. W., Brandt C. D. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J. 6:1987;159-163.
120. Smith D. W., Frankel L. R., Mathers L. H., Tang A. T. S., Ariagno R. L., Prober M. D. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infections. Pediatr Pulmonol. 13:1991;143-150.
121. Giffin F. J., Greenough A., Yuksel B. Antiviral therapy in neonatal chronic lung disease. Early Human Development. 42:1995;97-109.
122. Janai H. K., Stutman H. R., Zaleska M., Rub B. E. M., Marks M. I., Nussbaum E. Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J. 12:1993;214-218.
123. Law B. J., Wang E. E., Stephens D. Ribavirin does not reduce hospital stay (LOS) in patients with respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI). Pediatr Res. 37:1995;110A.
124. Meert K. L., Sarnaik A. P., Gelmini M. J., Lieh-Lai M. W. Aerosolizerd ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory disease: a prospective, double-blind randomized trial. Crit Care Med. 22:1994;566-572.
125. Moler F. W., Steinhart C. M., Ohmit S. E., Stidham G. L. Effectiveness of ribavirin in otherwise well infants with respiartory syncytial virus-associated respiartory failure. J Pediatr. 128:1996;422-428.
126. Ohmit S. E., Moler F. W., Monto A. S., Khan A. S. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. J Clin Epidemiol. 49:1996;963-969.
127. Halsey N. A., Chesney P. J., Gerber M. A. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics. 97:1996;137-140.
128. Law B. J., Wang E. E., MacDonald N. Does ribavirin impact on the hospital course of children with respiratory syncytial virus (RSV) infection? An analysis using the pediatric investigators collarborative network on infections in Canada (PICNIC) RSV database. Pediatrics. 99:1997;E7.
129. Mitchell I., Joffe A., Newth C. J. L. Ribavirin. Red Book Committee recommendations questioned. Pediatrics. 95:1995;319-319.
130. Randolph A. G., Wang E. E. L. Ribavirin for respiratory syncytial virus lower respiratory tract infection - A systematic overview. Arch Pediatr Adolesc Med. 150:1996;942-947.
131. Snell N. J. C. Economic and long-term bvenefits of ribavirin therapy on respiratory syncytial virus infection. Lung. 168(Suppl):1990;422-429.
132. Feldstein T. J., Swegarden J. L., Atwood G. F., Peterson C. D. Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy. Pediatrics. 96:1995;14-17.
133. Marquardt E. D. Cost of ribavirin therapy for respiratory syncytial virus infection. J Pediatrics. 126:1995;847.
134. Englund J. A., Sullivan C. J., Dehner L. P., Vercellotti G. M., Balfour H. J. Jr. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med. 109:1988;203-208.
135. Harrington R. D., Hooton T. M., Hackman R. C. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis. 165:1992;987-983.
136. Sparrelid E., Ljungman P., Ekelof-Andstrom E. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infection. Bone Marrow Transplant. 19:1997;905-908.
137. Eriksson B., Helgstrand E., Johansson N. G. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother. 11:1977;946-951.
138. Wray S. K., Gilbert B. E., Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 5:1985;39-48.
139. Wray S. K., Gilbert B., Noall M. W., Knight V. Mode of action of ribavirin: Effect of nucleotide pool alterations on influenza virus ribonucleoprotein syntheis. Antiviral Res. 5:1985;29-37.
140. Goswami B. B., Borek E., Sharma O. K. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun. 89:1979;830-836.
141. Hayden F. G. Combination antiviral therapy for respiratory virus infections. Antiviral Res. 29:1996;45-48.
142. Gruber W. C., Wilson S. Z., Throop B. J., Wyde P. R. Combined immunoprophylaxis and ribavirin therapy of respiratory syncytial virus (RSV) infection in the cotton rat. Pediatric Res. 21:1987;270-274.
143. DeVincenzo J. P., Leombruno D., Soiffer R. J., Siber G. R. Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant. 17:1996;1051-1056.
144. Whimbey E., Champlin R. E., Englund J. A. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant. 16:1995;393-399.
145. Wyde P. R., Wilson S. Z., Petrella R., Gilbert B. E. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antiviral Res. 7:1987;211-220.
146. Gilbert B. E., Wyde P. R., Ambrose M. W., Wilson S. Z., Knight V. Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res. 17:1992;33-42.
147. Englund J. A., Piedra P. A., Ahn Y. M., Gilbert B. E., Hiatt P. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 117:1990;313-320.
148. Englund J. A., Piedra P. A., Young-Min A., Gilbert B. E., Hiatt P. High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr. 125:1994;635-641.
149. McColl M. D., Corser R. B., Bremner J., Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant. 21:1998;423-425.
150. Shigeta S., Mori S., Watanabe J. In vitro antimyxovirus and anti-human immunodeficiency virus activities of polyoxometalates. Antivir Chem Chemother. 6:1995;114-122.
151. Ikeda S., Neyts J., Verma S., Wickramasinghe A., Mohan P., Declercq E. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob Agents Chemother. 38:1994;256-259.
152. Hosoya M., Balzarini J., Shigeta S., De Clercq E. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retrovirues, depending on the composition of the target amino acid sequences on the viral envelope glycoproteins. Antimicrob Agents Chemother. 35:1991;2515-2520.
153. Witvrouw M., Desmyter J., De Clercq E. Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chem Chemother. 5:1994;345-359.
154. Neyts J., Reymen D., Letourneur D. Differential antiviral activity of derivatized dextrans. Biochem Pharmacol. 50:1995;743-751.
155. Hasui M., Matsude M., Okutani K., Shigeta S. In vitro antiviral activities of sulfated polysacharides from a marine microalga (Cochlodinium polykritoides) against human immunodeficiency virus and other enveloped viruses. Int J Biol Macromol. 17:1995;293-297.
156. Wyde P. R., Meyerson L. R., Gilbert B. E. An in vitro evaluation of the antiviral activity of SP-303, an euphorbiaceae shrub extract, against a panel of respiratory virus. Drug Dev Res. 28:1993;467-472.
157. Lambert D. M., Barney S., Lambert A. L. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA. 93:1996;2186-2191.
158. Gilbert B. E., Wyde P. R., Wilson S. Z., Meyerson L. R. SP-303 treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res. 21:1993;37-45.
159. Wyde P. R., Ambrose M. A., Meyerson L. R., Gilbert B. E. The antiviral activity of SP-303, a natural polyphenolic polymer, against respiratory syncytial and parainfluenza type 3 viruses on cotton rats. Antiviral Res. 20:1993;145-154.
160. Chiba T., Shigeta S., Numazaki Y. Inhibitory effect of pyridobenzazoles on virus replication in vitro. Biol Pharm Bull. 18:1995;1081-1083.
161. Kolocouris N., Foscolos G. B., Kolocouris A. Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J Med Chem. 37:1994;2896-2902.
162. Wyde P. R., Moore-Poveda D. K., O'Hara B., Ding W-D., Mitsner B., Gilbert B. E. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture in cotton rats. Antiviral Res. 38:1998;31-42.
163. De Clercq E. Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections. Internatl J Antimicrobial Agents. 7:1996;193-202.
164. Balzarini J., Karlsson A., Wang L. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, a novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J Biol Chem. 268:1993;24591-24598.
165. De Clercq E., Cools M., Balzarini J. Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob Agents Chemother. 35:1991;679-684.
166. Shigeta S., Mori S., Baba M. Antiviral activities of ribavirin, 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob Agents Chemother. 36:1992;435-439.
167. De Clercq E., Murase J., Marquez V. E. Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol. 41:1991;1821-1829.
168. Shuto S., Obara T., Toriya M. New neplanocin analogues. 1. Synthesis of 6′-modified neplanocin A derivatives as broad-spectrum antiviral agents. J Med Chem. 35:1992;324-331.
169. Siddiqi S. M., Chen X., Schneller S. W. Antiviral enantiomeric preference for 5′-noraristeromycin. J Med Chem. 37:1994;551-554.
170. Siddiqi Sm., Chen X., Rao J., Schneller S. W. 3-deaza- and 7-deaza-5′ noraristeromycin and their antiviral properties. J Med Chem. 38:1995;1382-1384.
171. Siders J. A., Chen X., Schneller S. W. An epimer of 5′-noraristeromycin and its antiviral properties. J Med Chem. 37:1994;1382-1384.
172. Villanueva N., Navarro J., Cubero E. Antiviral effects of xanthate D609 on the human respiratory syncytial virus growth cycle. Virology. 181:1991;101-108.
173. Huang R. C., Panin M., Romito R. R., Huang Y. T. Inhibition of replication of human respiratory syncytial virus by 6-diazo-5-oxo-L-norleucine. Antiviral Res. 25:1994;269-279.
174. Chen X., Schneller S. W., Ikeda S. Synthesis and antiviral activity of 5′-deoxypyrazofuin. J Med Chem. 36:1993;3727-3730.
175. Chipps B. E., Sullivan W. F., Portnoy J. M. Alpha-2A-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis J. 12:1993;653-658.
176. Sung R. Y. T., Yin J., Oppenheimer S. J., Tam J. S., Lau J. Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a. Arch Dis Child. 69:1993;440-442.
177. Wyde P. R., Moore D. K., Pimentel D. M., Gilbert B. E., Nimrod R., Panet A. Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats. Antiviral Res. 31:1996;173-184.
178. Raineri I., Huang T. T., Epstein C. J., Epstein L. B. Antisense manganese superoxide dismutase mRNA inhibits the antiviral action of interferon-gamma and interferon-alpha. J Interferon Cytokine Res. 16:1996;61-68.
179. Jairath S., Vargas P. B., Hamlin H. A., Field A. K., Kilkuskie R. E. Inhibition of respiratory syncytial virus replication by antisense oligodeoxyribonucleotides. Antiviral Res. 33:1997;201-213.
180. Cirino N. M., Li G., Xiao W., Torrence P. F., Silverman R. H. Targeting RNA decay with 2′, 5′ oligoadenylate-antisense in respiratory syncytial virus-infected cells. Proc Natl Acad Sci USA. 94:1997;1937-1942.
181. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 177:1972;705-706.
182. Nizuma S., Shuto S., Matsuda A. New neplanocin analogues. The conversion of adenosine to neplanocin A, a carbocyclic nucleoside antibiotic with potent antiviral activity. Tetrahedron. 53:1997;13621-13632.
183. Wyde P. R., Ambrose M. W., Meyer H. L., Gilbert B. E. Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res. 14:1990;237-247.
184. De Clercq E. S-adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem Pharmacol. 36:1987;2567-2575.
185. Wyde P. R., Meyer H. L., Zolinski C. L., Gilbert B. E. Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res. 14:1990;215-226.
186. Robins M. J., Wnuk S. F., Yang X. D. Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5′,5′,6′,6′-tetradehydro-6′-deoxy-6′-halohomoadenosine analogues (4′-haloacetylene analogues derived from adenosine). J Med Chem. 41:1998;3857-3864.
187. Shigeta S., Mori S., Baba M. Inhibitory effect of pyridobenzoazoles on orthomyxo- and paramyxovirus replication in vitro. Antiviral Chem Chemother. 3:1992;171-177.
188. Yao Q., Compans R. W. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology. 223:1996;103-112.
189. Englund J. A., Matson D. O. Update on measles: Incidence rises after long decline. Pediatric Virol. 4:1989;1-4.
190. Field A. K. Viral targets for antisense oligonucleotides: a minireview. Antiviral Res. 37:1998;67-81.
191. Koschel K., Brinckmann U., Hoyningen-Huene V. V. Measles virus antisense sequences specifically cure cells persistently infected with measles virus. Virology. 207:1995;168-178.
192. Huang S. P., Shieh G. J., Lee L. Inhibition effect of Shengma-gegen-tang on measles virus in vero cells and human peripheral blood mononuclear cells. Am J Chinese Med. 1:1997;89-96.
193. Nakayama T., Urano T., Osano M., Maehara N., Sasaki K., Makino S. Measles virus and mumps virus induce gamma interferon differently in human lymphocyte cultures. J Infect Dis. 155:1987;1051-1053.
194. Lecciones J. A., Abejar N. H., Dimaano E. E. A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-alpha-n1 (Ins) in pediatric patients with measles. J Interferon Cytokine Res. 18:1998;647-652.
195. Forni A. L., Schluger N. W., Roberts R. B. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis. 19:1994;454-462.
196. Gururangan S., Stevens R. F., Morris D. J. Ribavirin response in measles pneumonia. J Infect Dis. 20:1990;219-221.
197. Banks G., Fernandez H. Clinical use of ribavirin in measles: a summarized review. Smith R. A., Knight V., Smith J. A.D., Clinical Applications of Ribavirin. 1980;203-209 Academic Press, New York.
198. Carmena J., Tornero C., Salcedo M., Perpinan J., Pons E. Pneumonia caused by measles in a pregnant woman with HIV antibodies. Response to treatment with immunoglobulins. Enferm Infecc Microbiol Clin. 14:1996;456-457.
199. Ross L. A., Kim K. S., Mason W. H. Jr, Gomperts E. Successful treatment of disseminated measles in patients with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. J Am Med Assoc. 88:1984;313.
200. Stogner S. W., King J. W., Black-Payne C., Bocchini J. Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. South Med J. 141:1993;1415-1418.
201. Top F. H. Jr, Buescher E. L., Bancroft W. H., Russell P. K. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis. 124:1971;155-160.
202. Top F. H. Jr. Control of adenovirus acute respiratory disease in U.S. army trainees. Yale J Biol Med. 48:1975;185-195.
203. Gordon Y. R., Romanowski E., Araullo-Cruz T. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenovirus isolates is serotype-dependent in vitro. Antiviral Res. 16:1991;11-16.
204. Murphy G. F., Wood D. J. Jr, McRoberts J. W., Henslee Downey P. J. Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin. J Urol. 149:1993;565-566.
205. Chacon M. J., Mohedo F. H., Mari J. M. N. Adenovirus pneumonitis successfully treated with intravenous ribvirin. Haematologica. 83:1998;1128-1129.
206. Ribaud P., Scieux C., Freymuth F., Morinet F., Gluckman E. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis. 28:1999;690-691.
207. Douglas R. G. Jr, Couch R. B. Parenteral inactivated rhinovirus vaccine: minimal protective effect. Proc Soc Exp Biol Med. 139:1972;899-902.
208. Perkins J. C., Tucker D. N., Knopf H. L. Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. Am J Epidemiol. 90:1969;319-326.
209. Douglas R. G. Jr, Couch R. B. Attenuation of rhinovirus type 15 for humans. Nature. 223:1969;213-214.
210. Monto A. S., Bryan E. R., Ohmit S. Rhinovirus infections in Tucumseh, Michigan: frequency of illness and number of serotypes. J Infect Dis. 156:1987;43-49.
211. Greenberg S. B., Harmon M. W., Johnson P. E. Activity of exogenous interferon in the human nasal mucosa. Fed Rep Biol Med. 35:1977;491-495.
212. Hayden F. G., Gwaltney J. M. Jr. Intranasal interferon-2 treatment of experimental rhinoviral colds. J Infect Dis. 150:1984;174-180.
213. Hayden F. G., Albrect J. K., Kaiser D. L., Gwaltney J. M. Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med. 314:1986;71-75.
214. Samo T. C., Greenberg S. B., Couch R. B. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis. 148:1983;535-542.
215. Sperber S. J., Levine P. A., Sorrentino J. V., Riker D. K., Hayden F. G. Ineffectiveness of recombinant interferon-serine nasal drops for prophylaxis of natural colds. J Infect Dis. 160:1989;700-705.
216. Douglas R. M., Moore B. W., Miles H. B. Prophylactic efficacy of intranasal alpah2-interferon against rhinovirus infections in the family setting. N Engl J Med. 314:1986;65-70.
217. Sperber S. J., Hunger S. B., Schwartz B. Anti-rhinoviral activity of recombinant and hybrid species of interferon alpha. Antiviral Res. 22:1993;121-129.
218. Douglas R. G. Jr, Betts R. F. Effect of induced interferon in experimental rhinovirus infection in volunteers. Infect Immun. 9:1974;506-510.
219. Panusarn C., Stanley E. D., Dirda V., Rubens M., Jackson G. G. The prevention of illness from rhinovirus infection by a topical interferon inducer. N Engl J Med. 291:1974;57-61.
220. Ohlin A., Hoover-Litty H., Sanderson G. Spectrum of activity of soluble intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates. Antivir Chem Chemother. 38:1999;1413-1141.
221. Marlin S. D., Staunton D. E., Springer T. A., Stratowa C., Sommergruber W., Merluzzi V. J. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature. 344:1990;70-72.
222. Turner R. B., Wecker M. T., Pohl G. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. J Am Med Assoc. 281:19xx;1797-1804.
223. Lineberger D. W., Graham D. J., Tomassini J. E., Colonno R. J. Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor. J Virol. 64:1990;2582-2587.
224. Martin S., Casasnovas J. M., Staunton D. E., Springer T. A. Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules. J Virol. 67:1993;3561-3568.
225. Andries K., Dewindt B., Snoeks J., Willebrords R., Stokgbroekx R., Lewi P. J. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis of a more rational screening program. Antiviral Res. 16:1991;213-225.
226. Philpotts R. J., Jones R. W., DeLong D. C., Reed S. E., Wallace J., Tyrrell D. A. J. The activity of enviroxime against rhinovirus infection in man. Lancet. 1:1981;1342-1344.
227. Wyde P. R., Wilson S. Z., Gilbert B. E., Six H. R., Knight V. Activity against rhinoviruses, toxicity and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother. 32:1988;890-895.
228. Al-Nakib W., Tyrrell D. A. J. Drugs against rhinoviruses. J Antimicrob Chemother. 30:1992;115-117.
229. Al-Nakib W., Higgins P. G., Barrow I., Tyrrell D. A. J., Lenox-Smith I., Ishitsuka H. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers. J Antimicrob Chemother. 20:1987;887-892.
230. Philpotts R. J., Higgins P. G., Willman J. S., Tyrrell D. A. J., Lenox-Smith I. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. J Antimicrob Chemother. 14:1984;403-409.
231. Al-Nakib W., Higgins P. G., Vanden Bussch G., Taylor N., Janssen P. A. J. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother. 33:1989;522-525.
232. Hayden F. G., Albrecht J. K., Kaiser D. L., Gwaltney J. M. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother. 36:1992;727-732.
233. Barrow G. I., Higgins P. G., Tyrrell D. A. J., Andries K. An appraisal of the efficacy of the antiviral R61837 in rhinovirus infections in human volunteers. Antivir Chem Chemother. 1:1990;279-283.
234. Woods M. G., Diana G. D., Rogge M. C., Otto M. J., Dutko F. J., McKinlay M. A. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother. 32:1989;2069-2074.
235. Shepard D. A., Heinz B. A., Rueckert R. R. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus. J Virol. 67:1993;2245-2254.
236. Turner R. B., Dutko F. J., Goldstein N. H., Lockwood G., Hayden F. G. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother. 37:1993;297-300.
237. McKinlay M. A., Pevear D. C., Rossmann M. G. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol. 46:1992;635-654.
238. Dragovich P. S., Webbger S. E., Babine R. E. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem. 41:1998;2806-2818.
239. Wang Q. M., Johnson R. B., Jungheim L. N., Cohen J. D., Villarreal E. C. Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides. Antimicrob Agents Chemother. 42:1998;916-920.
240. Webber S. E., Tikh J., Worland S. T. Design, synthesis and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J Med Chem. 39:1996;5072-5082.
241. Venkatraman S., Kong J., Nimkar S., Wang Q. M., Aube J., Hanzlik R. P. Design, synthesis, and evaluation of azapeptides as substrates and inhibitors for human rhinovirus 3C protease. Bioorg Med Chem Lett. 9:1999;577-580.
242. Dragovich P. S., Prins T. J., Zhou R. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem. 42:1999;1203-1212.
243. Hamdouch C., de Blas J., del Prado M. 2-Amino-3-substituted-6-[(E)-1-phenyl-2-(N-methy, lcarbamoyl) vinyl] imid azo[1,2-a]pyridines as a novel class of inhibitors of human rhinovirus: stereospecific synthesis and antiviral activity. J Med Chem. 42:1999;50-59.
244. Hamdouchi C., de Blas J., del Prado M., Gruber J., Heinz B. A., Vance L. 2-amino-3-substitutesd-6-[(E)-1-phenyl-2-(N-methylcarbamoyl) vinyl]imid azo[1,2-2]pyridines as a novel class of inhibitors of human rhinovirus: stereospecific synthesis and antiviral activity. J Med Chem. 42:1999;50-59.
245. Gwaltney J. M. Jr, Druce H. M. Efficacy of brompheniramine maleate for the treatment of rhinovirus colds. Clin Infect Dis. 25:1997;1188-1194.
246. Tebbe M. J., Spitzer W. A., Victor F. Antirhino/enteroviral vinylacetylene benzimidazoles: a study of their activity and oral plasma levels in mice. J Med Chem. 40:1997;3937-3946.
247. Oren D. A., Zhang A., Nesvadba H., Rosenwirth B., Arnold E. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. J Mol Biol. 259:1996;120-134.
248. Rozhon E., Cox S., Buontempo P. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res. 21:1993;15-35.
249. Gwaltney M. M. Jr. Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis. 166:1992;776-782.
250. Dearden C., Al-Nakib W., Woestenborghs R., Tyrrel D. Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Arch Virol. 109:198;71-81.
251. Yasin S. R., Al-Nakib W., Tyrrell D. A. J. Isolation and preliminary characterization of chalcone Ro 09-0410-resistant human rhinovirus type 2. Antiviral Chem Chemother. 1:1990;149-154.
252. Heinz B. A., Rueckert R. R., Shepard F. K. Genetic and molecular analysis of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol. 63:1989;2476-2485.
253. Dewindt B., van Eemeren K., Andries K. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses. Antiviral Res. 25:1994;67-72.
254. Ninomiya Y., Shimma N., Ishitsuka H. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides. Antiviral Res. 13:1990;61-74.
255. Diana G. D., Treasurywala A. M., Bailey T. R., Oglesby R. C., Pevear D. C., Dutko F. J. A model for compounds active against human rhinovirus-14 based on x-ray crystallography data. Antimicrob Agents Chemother. 37:1990;297-300.
256. Badger J., Minor I., Kremer M. J. Structural analysis of a series of antiviral agents complexed with human rhinoviruses. Proc Nat Acad Sci USA. 85:1988;3304-3308.
257. Diana G. D., Oglesby R. C., Akullian V. Structure-activity studies of 5-[[4-4,5-dihdro-2-oxazolyl) phenoxyl]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating. J Med Chem. 30:1987;383-388.
258. Rossmann M. G., Arnold E., Erickson J. W. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 317:1985;145-153.
259. Badger J., Krishnaswamy S., Kremer M. J. Three-dimensional structures of drug-resistant mutants of human rhinovirus 14. J Mol Biol. 207:1989;163-174.
260. Wade R. C., McCammon J. A. Binding of an antiviral agent to a sensitive and a resistant human rhinovirus. Computer stimulation studies with sampling of amino acid side-chain conformations. I. Mapping the rotamers of residue 188 of viral protein 1. J Mol Biol. 225:1992;679-696.
261. Wang W., Lee W. M., Mosser A. G., Rueckert R. R. WIN 52035-dependent human rhinovirus 16: assmbly deficiency caused by mutations near the canyon surface. J Virol. 72:1998;1210-1218.
262. Wang Q. M. Protease inhibitors as potential antiviral agents for the treatment of picornaviral infections. Prog Drug Res. 52:1999;197-219.
263. Richman D. D. The implications of drug resistance for strategies of combination antiviral chemothery. Antiviral Res. 29:1996;31-33.
264. Madren L. K., Shipman C. Jr, Hayden F. G. In vitro inhibitory effects of combinations of anti-influenza agents. Antivir Chem Chemother. 6:1995;109-113.
265. Desormeaux A., Bergeron M. G. Liposomes as drug delivery system: A strategic approach for the treatment of HIV infection. J Drug Targeting. 6:1998;1-15.
266. Gregoriadis G. Engineering liposomes for drug delivery: Progress and problems. Trends Biotechnol. 13:1995;527-537.
267. Tari A., Khodadadian M., Ellerson D., Deisseroth A., Lopez Berestein G. Liposomal delivery of oligodeoxynucleotides. Leuk Lymphoma. 21:1996;93.
268. Gilbert B. E., Knight V. Pulmonary delivery of antiviral drugs in liposome aerosols. Semin Pediatr Infect Dis. 7:1996;148-154.
269. Gilbert B. E. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med. 1996;111-122.
270. Jones R. J., Bischofberger N. Nucleotide prodrugs. Antiviral Res. 27:1995;1-17.
271. Alper J. Computer-aided design of antiviral agents. ASM News. 56:1990;269-271.
272. McCammon J. A. Computer-aided design. Science. 238:1987;486-491.
273. Kim C. U. Rational drug design of orally active influenza neuraminidase inhibitors: Discovery and development of GS 4104. Med Chem Res. 8:1998;392-399.
274. Selway C. N., Terrett N. K. Parallel-compound synthesis: methodology for accelerating drug discovery. Bioorg Med Chem. 4:1996;645-654.